These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 24285837)
1. Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice. Lee S; Mittler RS; Moore ML J Immunol; 2014 Jan; 192(1):293-9. PubMed ID: 24285837 [TBL] [Abstract][Full Text] [Related]
2. Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. Lee S; Stokes KL; Currier MG; Sakamoto K; Lukacs NW; Celis E; Moore ML J Virol; 2012 Dec; 86(23):13016-24. PubMed ID: 23015695 [TBL] [Abstract][Full Text] [Related]
3. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508 [TBL] [Abstract][Full Text] [Related]
4. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. Olson MR; Hartwig SM; Varga SM J Immunol; 2008 Dec; 181(11):7958-68. PubMed ID: 19017987 [TBL] [Abstract][Full Text] [Related]
7. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317 [TBL] [Abstract][Full Text] [Related]
8. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells. Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098 [TBL] [Abstract][Full Text] [Related]
9. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice. Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682 [TBL] [Abstract][Full Text] [Related]
10. Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. Stevens WW; Sun J; Castillo JP; Braciale TJ Viral Immunol; 2009 Jul; 22(4):243-51. PubMed ID: 19594395 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease. Srinivasa BT; Fixman ED; Ward BJ Eur J Immunol; 2014 Aug; 44(8):2349-59. PubMed ID: 24796717 [TBL] [Abstract][Full Text] [Related]
12. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131 [TBL] [Abstract][Full Text] [Related]
13. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice. Boyoglu-Barnum S; Chirkova T; Todd SO; Barnum TR; Gaston KA; Jorquera P; Haynes LM; Tripp RA; Moore ML; Anderson LJ J Virol; 2014 Sep; 88(18):10569-83. PubMed ID: 24990999 [TBL] [Abstract][Full Text] [Related]
16. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. Crowe JE; Firestone CY; Murphy BR J Immunol; 2001 Oct; 167(7):3910-8. PubMed ID: 11564809 [TBL] [Abstract][Full Text] [Related]
17. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells. Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002 [TBL] [Abstract][Full Text] [Related]
18. Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection. Muralidharan A; Russell M; Larocque L; Gravel C; Li C; Chen W; Cyr T; Lavoie JR; Farnsworth A; Rosu-Myles M; Wang L; Li X Sci Rep; 2018 Nov; 8(1):16648. PubMed ID: 30413743 [TBL] [Abstract][Full Text] [Related]
19. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. Jorquera PA; Choi Y; Oakley KE; Powell TJ; Boyd JG; Palath N; Haynes LM; Anderson LJ; Tripp RA PLoS One; 2013; 8(9):e74905. PubMed ID: 24040360 [TBL] [Abstract][Full Text] [Related]
20. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]